Moderna, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Moderna, Inc. (MRNA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$747.06 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-02-26
- Moderna, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -$123.12M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was -$123.19M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-06-30 was -$135.05M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-03-31 was -$132.66M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$747.06M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$514.02M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$401.86M.
- Moderna, Inc. net income (loss) available to common stockholders, basic for fiscal 2017 was -$269.84M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$747.06M 10-K · filed 2021-02-26 | |||
| 2019-12-31 | -$123.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$246.31M derived: sum of 2 quarters · filed 2021-02-26 | -$381.36M derived: sum of 3 quarters · filed 2021-02-26 | -$514.02M 10-K · filed 2021-02-26 |
| 2019-09-30 | -$123.19M 10-Q · filed 2019-11-06 | -$258.25M derived: sum of 2 quarters · filed 2019-11-06 | -$390.90M 10-Q · filed 2019-11-06 | -$535.00M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$135.05M 10-Q · filed 2019-08-08 | -$267.71M 10-Q · filed 2019-08-08 | -$411.81M derived: sum of 3 quarters · filed 2021-02-26 | -$499.63M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$132.66M 10-Q · filed 2019-05-09 | -$276.76M derived: sum of 2 quarters · filed 2021-02-26 | -$364.57M derived: sum of 3 quarters · filed 2021-02-26 | -$458.66M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$144.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$231.92M derived: sum of 2 quarters · filed 2021-02-26 | -$326.00M derived: sum of 3 quarters · filed 2021-02-26 | -$401.86M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$87.82M 10-Q · filed 2019-11-06 | -$181.90M derived: sum of 2 quarters · filed 2019-11-06 | -$257.76M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$94.08M 10-Q · filed 2019-08-08 | -$169.94M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$75.86M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | -$269.84M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$230.31M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |